Navigation Links
A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing

GOTHENBURG, Sweden, November 25, 2011 /PRNewswire/ --

Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial.

- It's a big and important step to test the vaccine on humans for the first time. Our animal studies have shown good results, so we feel safe to continue, says Jamal El-Mosleh, CEO of Immunicum.

Immunicum's patented cancer vaccine is based on over 20 years of research in the field of transplantation immunology and activates the body's own immune system to attack tumor cells. The Nobel Prize in Medicine was recently awarded the discoverer of dendritic cells and their role in immunological reactions, the same type of cells that Immunicum bases its vaccines on.

- However, our vaccines differ from other cancer vaccines. Traditionally, dendritic cell-based cancer vaccines are made from patients' own cells. This means that each vaccine must be specially made for each patient, which is expensive, complex and takes time. Moreover, it is physically stressful for the patient who is seriously ill, says Jamal El-Mosleh.

Immunicum's vaccine is based on using dendritic cells from healthy individuals and can thus be mass-produced, leading to significant commercial advantages.

The vaccine has been tested in animal studies to examine its therapeutic effect and tumors were reduced in both weight and volume. Toxicity studies have also been conducted to investigate possible side effects, especially with a focus on autoimmune diseases. The study showed no evidence of adverse side effects.

Through the green light from the Medical Products Agency, a clinical phase I/II trial will be initiated within the next few months on twelve patients with metastatic renal cancer. To finance the trial, Immunicum secures the largest capital injection in the company's history through a successful new share issue.

- The study will last for about a year and we will evaluate both safety and efficacy of the vaccine, says Jamal El-Mosleh.

More on Immunicum

Immunicum develops therapeutic cancer vaccines. The patented technology is based on over 20 years of research in the field of transplantation immunology and activates the body's own immune system to attack harmful substances such as tumor cells. Unlike competing dendritic cell-based cancer vaccines, Immunicum's vaccines are able to mass produce.

For further information contact: Jamal El-Mosleh, CEO of Immunicum,

SOURCE Immunicum
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
2. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
3. Cell-based alternative to animal testing
4. Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
5. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
6. O2h and Hypoxium Announce an Agreement to Offer Hypoxiums Specialised In Vitro, Cell-Based Oncology Assays via O2hs Biology Affiliate Program
7. Stemgent, CellDesign Sign Co-Exclusive Marketing Agreement on Stem Cell-Based Adipocyte Research Products
8. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
9. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
10. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
11. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
Post Your Comments:
(Date:10/8/2015)... MADISON, N.J. , Oct. 8, 2015  Genetic ... guidelines may aid the identification of more couples at ... to a study presented today at the 2015 American ... through October 10 in Baltimore, Maryland ... from Quest Diagnostics (NYSE: DGX ) are presenting ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... , ... October 08, 2015 , ... Talon Innovations, a ... Aerospace and other technology-driven industries, announces that it is one of three finalists for ... Midsize Company.” On Thursday, September 25 Talon Innovations was recognized as a nominee ...
Breaking Biology Technology:
... Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today reported a summary of recent ... and nine months ended September 30, 2011. ... the first nine months of this year," said James ...
... Nov. 10, 2011 Theravalues, a Japan ... impacts positively on the prevention of heart failure and ... the human clinical trial started with the registration in ... Organization Kyoto Medical Center and University of Shizuoka, Japan, ...
... Kluwer Pharma Solutions, a leading provider of scientific information ... to investors through Bloomberg Tradebook,s Independent Research Provider (IRP) ... in Thought™, Wolters Kluwer Pharma Solutions, research ... pharmaceutical drugs and medical devices. ...
Cached Biology Technology:
(Date:9/10/2015)... Report Details The global wearable ... previous expectations of revenues, consumer adoption and even technological ... which wearables begin to achieve that mass market acceptance ... reasons is the entrance of Apple to the SmartWatches ... but the overall size of the wearable technology market. ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security ... and solution-based milestones, furthering the company,s commitment to ... online fraud. NuData Security,s online fraud ... the company,s growth cycle. The product combines continual ... determine good user behavior from fraudulent behavior, allowing ...
(Date:9/2/2015)... Sept. 2, 2015 About hand geometry biometrics ... banks, government organizations, telecommunication and hospitals as well as ... badges, and numeric keypads are used to prevent unauthorised ... palm and fingers of an individual, width of the ... with infrared light and reflectors can be used for ...
Breaking Biology News(10 mins):
... School of Medicine (BUSM) have found a link ... HIV-infected persons. The study appears online in the ... Deficiency Syndromes., Alcohol use is common among HIV-infected ... has been examined in in-vitro, animal and human ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... The sensor components resemble a pregnancy test ...
... biological systems engineering, is leading the team of ... Sciences ( ) at Virginia Tech ( ... convert poultry litter into bio-oil, providing an economical ... issues. Agblevor will present the research during ...
Cached Biology News:
... The high-performance triple quadrupole 1200L sets ... today's cost-conscious environment - incorporating the ... for all liquid chromatography analytical needs. ... interface and the Transmission Quadrupole Analyzer ...
C1-inhibitor (C1-INH)...
... ATP-Free using Mo Bio luciferase assay. Mo Bio ... that will allow you to certify your products ... enable you to deliver them to your customers ... detection limit is 3.5 x 10-12 /l, which ...
Choriongonadotropin (human, hCG)...
Biology Products: